Background and Aims: Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) estimations of glomerular filtration rate (eGFR), compared to modification of diet in renal disease (MDRD), have superior performance in predicting renal, cardiovascular and mortality events. Cystatin-C further improves prediction. Our primary aim was to assess the change in prevalence and classification of CKD in converting from MDRD to CKD-EPI in an unselected primary care CKD population. Our secondary aims were to determine the eligibility for cystatin-C testing based on National Institute for Health and Care Excellence guidance and the associated costs. Methods: eGFR data from an unselected UK primary care CKD cohort was studied to assess reclassification of CKD stages from MDRD to CKD-EPI, suitability for cystatin-C testing and its associated cost. Results: A total number of 24,660 individuals had ≥2 MDRD eGFR results <60 mL/min/1.73 m 2 >3 months apart (7.0% of adult population). The mean age was 75.2 (SD 11.4 years) with 15,265 (61.9%) females. Mean eGFR was 2.88 mL/min/1.73 m 2 lower with CKD-EPI eGFR versus MDRD eGFR (49.7 vs. 46.8, t test p < 0.0001, 95% CI 2.85-2.91). 12.0% of individuals were re-categorised to a more or less advanced CKD stage, and 1.3% to a less advanced stage. The percentage of the population categorised as 3a-A1 CKD-EPI and therefore potentially suitable for cystatin-C was 2.8%. The estimated initial cost is €67.5 (£57.2) million with annual costs of €2.7 (£2.3) million for the United Kingdom. Conclusions: The mean eGFR was lower with the CKD-EPI formula and individuals were more likely to be reclassified to more advanced CKD. This may be related to the higher mean age of this unselected population compared to previous studies. Refinements of eGFR formulae, CKD definitions and cystatin-C eligibility in unselected populations are required.
Introduction
Chronic kidney disease (CKD) is a common condition affecting approximately 7% of the adult population in primary care [1, 2] . Glomerular filtration rate (GFR) is the gold-standard measure of kidney function but is complex to measure and impractical in everyday clinical practice. Introduced into widespread clinical practice 10 years ago, formulaic estimations of GFR (eGFR) were intended to allow more accurate classification of CKD severity compared to serum creatinine alone [3] . Several creatinine-DOI: 10.1159/000487091 based equations of varying complexity are available for estimating measured GFR, but initially the modification of diet in renal disease (MDRD) eGFR equation [4] entered into clinical practice in the United Kingdom, supported by CKD guidance from the National Institute for Health and Care Excellence (NICE) [5] . However, the alternative CKD-Epidemiology Collaboration (CKD-EPI) eGFR formula [6] may perform better with less bias, especially at higher GFR. It is also superior to the MDRD equation in predicting hard endpoints including time to death, cardiovascular (CV) events and end-stage renal disease [7] . Other eGFR equations are based on the serum concentration of other substances, most notably cystatin-C [8] .
In an effort to further increase the sensitivity of risk stratification in CKD, NICE CKD guidance was updated and currently recommends the use of the CKD-EPI eGFR equation, combined in some circumstances with cystatin-C for staging of CKD [9] . Specifically, this guidance suggests combining both measures of CKD-EPI and cystatin-C together to confirm or rule out CKD in individuals with potential CKD stage 3a but no proteinuria (albumin:creatinine ratio [ACR] <3 mg/mmol) [9] . This recommendation was based on an estimation that the additional healthcare costs related to higher false-positive CKD diagnoses were greater than the additional costs of cystatin-C measurement for this group.
However, this updated guidance has been controversial and not widely adopted, despite evidence suggesting a dual biochemical approach to CKD classification may better predict patient outcomes [8, 10, 11] . In England and Wales, many laboratories continue to report MDRD eGFRs [12] , and the uptake of cystatin C eGFR into clinical practice has been poor. This inertia may be due to guideline fatigue, concerns around workload associated with the implementation of necessary changes by laboratories, and/or costs associated with the resulting need to re-classify some patients to a different CKD stage in primary care.
To our knowledge, no study has examined the implications of changing from the MDRD to the CKD-EPI eGFR equation for CKD classification in an unselected primary care population, nor quantified the resulting numbers of patients who would subsequently require additional eGFR testing by cystatin-C. We therefore used a large UK primary care-based CKD cohort to first assess the change in prevalence and classification of CKD if all existing MDRD eGFRs were converted to CKD-EPI eGFRs; second, to determine how many patients would fulfill eligibility criteria for an additional cystatin-C eGFR test based on prevailing NICE guidance; and third to estimate the initial and ongoing costs associated with this conversion.
Methods
We analysed kidney function data from the "Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease" (PSP-CKD) study (ClinicalTrials.gov Identifier: NCT01688141) cohort [13] . PSP-CKD utilised "IMproving Patient care and Awareness of Kidney disease progression Together" (IMPAKT), a freely available, web-based CKD audit and quality improvement software tool [14] to support a nurse led CKD management programme in 49 UK general practices.
To identify and monitor CKD patients registered at a general practice IMPAKT accesses the practice IT system and uses Morbidity Information Query and Export Syntax (MIQUEST) search methodology to execute queries to identify all adult patients with at least 2 MDRD eGFR values of <60 mL/min/1.73 m 2 , ≥90 days apart, at any time in the 5 years prior to enrolment of the practice into the study. IMPAKT also extracts other coded CKD-relevant data including anthropometric, demographic, medical history, prescribed medications, blood and urine test results for all patients with CKD stages 3-5. Individuals receiving maintenance dialysis or with a renal transplant were excluded. In PSP-CKD, data extraction was initially performed at the time of consent and randomisation (baseline, T = 0), and then at 6 monthly intervals thereafter for up to 42 months. A pseudonymised dataset from each practice was exported to the University of Leicester Clinical Trials Unit to assemble a prospective database from all participating practices. The study underwent full ethical review from the region's research Ethics Committee and informed consent was given by the general practices involved in the study.
For the current study, serum creatinine values held in the PSP-CKD database were used to calculate both MDRD and CKD-EPI eGFRs. At all time-points, the relevant clinical chemistry laboratories utilised the Jaffe method for measurement of serum creatinine. eGFRs were calculated from serum creatinine data for the T = 0 time point, and then for new individuals from each subsequent 6 monthly time point, using standardised formulae [4, 6] . For CKD-EPI, κ = 0.7 (females) or 0.9 (males), α = -0.329 (females) or -0.411 (males), "min" indicates the minimum of S Cr /κ or 1, and "max" indicates the maximum of S Cr /κ or 1. Serum creatinine values in µmol/L were converted to mg/dL by multiplying by 0.0113.
Proteinuria data was derived from urine dipstick results, ACR and protein:creatinine ratio values. Results were treated hierarchically with ACR first due to its better correlation to 24 h urine protein measurement, the gold standard of measurement. Urine dipstick was last in the hierarchy. Individuals were assigned, using eGFR and proteinuria data, to a CKD stage based on KDIGO guidelines [15] . Summary cohort data are reported for continuous outcomes as mean ± SD and for categorical variables as counts and percentage. The t test was used for comparison of difference in means and net re-classification was calculated based on re-classification to more and less advanced CKD stages. Simple eGFR re-categorisation was initially calculated for the study baseline population. Identification and re-classification were then performed for each subsequent time period. MDRD eGFR values were plotted against CKD-EPI eGFR values for all time points and a linear best fit line was plotted.
Patient eligibility for cystatin-C testing was determined based on the criteria described in current NICE CKD guidance for England and Wales [9] . This suggested the use of cystatin-C testing for individuals with a "borderline diagnosis" of CKD to "reduce overdiagnosis." NICE CKD guidance therefore suggested that cystatin-C should be considered in individuals with a CKD-EPI eGFR of 45-59 mL/min/1.73 m 2 , sustained for at least 90 days and no proteinuria (ACR less than 3 mg/mmol).
Cost estimates were based on 2016 standardised national unit costs for health and social care where available [16] . Where not available, cost changes were calculated from the NICE 2014 guidance [17] with adjustment for inflation, using the Consumer Price Index, a national UK standard for inflation [18] . All future costs were based on 2017 estimated costs and included calculations of those costs related to taking blood and processing serum cystatin-C tests. The overall costs of cystatin-C were calculated based on these plus the additional related costs of interpretation and potential patient management decisions in primary care. General practitioner consultation times were assumed to be 10 min per patient, the same as the 2014 NICE guidance [17] . All statistical analysis, including recalculation of eGFRs, was performed using Stata version 14.0.
Results
Altogether 49 GP practices, with 353,256 registered patients ≥18 years of age, were recruited into the PSP-CKD study at baseline. Initially, 21,544 individuals had ≥2 MDRD eGFR results <60 mL/min/1.73 m 2 at least 3 months apart. Individuals were eligible to enter the study at each sixth-monthly, data-collection time point and for this analysis, a total of 24,660 individuals were included across the study's time period. Table 1 shows selected baseline characteristics of the cohort. At entry into the study, 10,031 (46.6%) individuals were categorised by MDRD eGFR as CKD stage 3a and proteinuria stage A1 (3a-A1). Table 2 shows the differences in CKD stage classification of the baseline PSP-CKD study population when determined by either the MDRD or CKD-EPI eGFR equations. A scatter plot of all MDRD and CKD-EPI eGFRs is shown in Figure 1 with staging reclassification shown in Table 2 . At baseline, compared to MDRD eGFR, the use of CKD-EPI eGFR resulted in re-classification of 2,871 (13.3%) CKD patients to a different CKD stage, with 2,599 (12.0%) moving to a more advanced CKD stage and 272 (1.3%) moving to a less advanced CKD stage. Two hundred and forty-nine (1.2%) individuals with MDRD stage 3a CKD were re-classified by CKD-EPI to stage 2. The mean change in eGFR with conversion to CKD-EPI eGFR was -2.88 mL/min/1.73 m 2 (95% CI -2.85 to -2.91, t test, p < 0.0001).
From among 9,849 individuals, 39.9% of the CKD population and 2.48% of the adult population were classified as CKD-EPI stage 3a-A1, thus potentially being eligible for a cystatin-C eGFR according to NICE guidance [9] . Since KDIGO CKD guidance differs slightly by suggesting cystatin-C eGFR in CKD 3a-A1 where individuals had no other risk factors for CKD [15] , we further classified this group by the absence coded diagnoses for diabetes mellitus (DM) or hypertension (HTN). Of the total number, 2,264 individuals (9.2%) had no history of HTN or DM and 929 (41.0%) of them were classified as CKD-EPI CKD 3a-A1.
Based on similar assumptions to those used by NICE on the economic evaluation of cystatin-C, we estimated the initial and ongoing costs for cystatin-C measurement. The cost of performing a single test of cystatin-C, including phlebotomy costs was estimated to be €7.02 (£5.95). With the addition of primary care physician costs, the total cost estimate was €53.04 (£44.95) per patient. From the UK mid-2015 adult population of 51.3 million [19] , 1.3 million individuals (2.48% of the adult population) were estimated to be eligible for cystatin-C. When primary care consultation costs [17] were included, a cost estimate of €67.5 (£57.2) million for implementing cystatin-C testing for the eligible UK adult population was calculated. The annual cost for cystatin-C testing in incident CKD 3a-A1 patients was calculated to be €2.7 (£2.3) million for 50,850 patients (0.1% of the adult population). Table 3 shows the numbers underpinning these calculations.
Discussion
The evolution of eGFR formulae has been driven by a need for better prediction of 'hard' outcomes such as ESRF, CV events and mortality [7] . The derivation of both the MDRD and CKD-EPI has been through the collaborative combination of CKD research cohorts [4, 6] , generally including individuals with well-phenotyped CKD, and also with heavy proteinuria, and/or of younger age. While KDIGO guidelines have consolidated CKD staging into secondary care [15] , national guidelines such as NICE in the UK [9] strongly influence the primary care approach to CKD, where quantitatively the vast majority of care occurs. Therefore, the impact of these latter national guidelines is important in allocating healthcare resources.
Previous studies have suggested that the use of the CKD-EPI formula would reduce the prevalence of CKD and allow focus on individuals at higher risk for renal and CV outcomes [7] . CKD-EPI eGFR is more accurate, less biased and more precise than the MDRD formula in estimating measured GFR [6] . For a given eGFR, CKD-EPI is also a better predictor of renal, CV and mortality endpoints [7] . Used in isolation, cystatin-C and CKD-EPI eGFRs have similar levels of bias and precision [20] . However, this is improved with the combination of EPI-CKD and cystatin-C eGFR formulae. In CKD, risk prediction for both all-cause and CV mortality is improved with either cystatin-C alone or in combination with CKD-EPI eGFR [8] .
The first finding of our study suggests that overall in an unselected primary care CKD population, re-classification of CKD stage by CKD-EPI results most commonly in transfer of individuals to a more advanced stage of CKD, with a mean reduction in eGFR of around 3 ml/ min/1.73m
2 . This is in contrast to previous findings where such reclassification led to more patients with less ad- Between T1 and T2, one practice underwent a merger with another practice outside of the study and hence the total population rose by just over 13,000 adults.
* Estimated mid-2015 UK adult population from ONS [19] .
DOI: 10.1159/000487091 vanced CKD stages [7] . Therefore, this suggests that without the introduction of cystatin-C testing, the prevalence of CKD would arbitrarily rise with the use of the CKD-EPI formula instead of MDRD. The second finding of our study identifies the potential costs of testing a relatively large proportion, in the region of 3-4%, of the adult population to attempt to rule out CKD. The current data show that if all eligible CKD-EPI KDIGO stage 3a-A1 patients were to undergo cystatin-C as per prevailing guidance [9] , then approximately 2.5% of the adult population would potentially qualify for cystatin-C with a total initial cost of €67.5 (£57.2) million to the UK health service. This figure does not account for the approximate 25% of the current cohort lacking a proteinuria measurement, and thus may underestimate the true population eligible. Indeed, NHANES data suggests that 3.6% of the adult population may be eligible for cystatin-C measurement under the NICE criteria [15] . On an individual level, combined cystatin-C and creatinine measurement provides incremental improvement in predicting measured GFR and hard outcomes in individuals. It would though be associated with substantial initial costs to the healthcare system, even when limited to CKD stage 3a-A1. This therefore brings into question whether cystatin-C measurement in CKD management is the most appropriate use of resources from a public health perspective.
The present cohort is probably the largest CKD-specific primary care cohort worldwide, and is derived from a total adult population of approximately 350,000 individuals. The cohort's unselective nature from a large primary care CKD population is one of its major strengths. This representativeness compared to other, mainly secondary care-based CKD studies has allowed the study of the true rates of CKD reclassification from MDRD to CKD-EPI. The difference in reclassification compared to previous studies [7] is mainly explained by a higher mean age in our unselected primary care CKD population (online suppl. material, see www.karger.com/ doi/10.1159/000487091). Indeed, sub-analysis of the CKD Prognosis Consortium results suggests that those individuals reclassified to a more advanced CKD category were more likely to have a higher mean age and conversely a lower mean age if reclassified to a less advanced CKD stage [7] . Further, a recent smaller study of 600 older individuals with a median age of 87 years both with and without CKD suggested a similar reduction of 2.7 mL/min/1.73 m 2 in eGFR when conversion between MDRD and CKD-EPI was performed [21] .
Other studies have also considered the impact of eGFR formulae reclassification in older populations compared to measured GFR. The CKD-EPI formula has been shown to be more accurate and less biased than the MDRD formula in an older cohort with a mean age of 80 [22] . The more recently developed Berlin Initiative Study eGFR formulae may outperform both in older individuals [23] .
The present study has a number of limitations. First, as the study population was defined by an MDRD eGFR <60 mL/min/1.73 m 2 , we were unable to assess re-classification from MDRD eGFR ≥60 mL/min/1.73 m 2 to CKD-EPI eGFR <60 mL/min/1.73 m 2 . Based on previous literature, it is predicted that this classification would be relatively small [7] , but the findings of the current study suggest this population may be larger than previously anticipated. This may be another factor that underestimates the true eligibility for cystatin C in the whole adult population. Second, the current study is unable to assess the impact of this reclassification on predicting renal and CV outcomes and whether all individuals with CKD 3a-A1 should be considered for cystatin-C measurement or a specific sub-population within this group [19] . Finally, this analysis of cystatin-C includes a large proportion of missing data for proteinuria classification. Again, this is likely to underestimate the potential population requiring cystatin-C measurement. The current results suggest that if individuals with established CKD risk factors such as DM and HTN are assumed to have confirmed CKD and therefore do not require a confirmatory cystatin-C, then only 9.2% of the CKD 3a-A1 population would require cystatin C.
The current cost analysis makes a number of assumptions. It was assumed that cystatin-C measurement was taken at a separate time to a second confirmatory eGFR measurement. This is because approximately a third of our cohort who had a single eGFR <60 mL/min/1.73 m 2 had a repeat eGFR ≥60 mL/min/1.73 m 2 and therefore would not require a cystatin-C measurement. Like NICE [9] , we were unable to establish a precise unit cost for cystatin-C measurement and therefore the cost estimate was based on that used by NICE with consideration of price inflation. As this was a cross-sectional analysis of eGFR measures, it was not possible to update any of the NICE's economic assumptions regarding the future impact on management of ruling out CKD for individuals.
While the current study cannot provide additional guidance and cost-benefit analysis regarding which subgroups of CKD to test, currently the proportion of the adult populations recommended for cystatin-C measurement is substantial in both number and cost. Therefore, Nephron 2018;139:39-46 DOI: 10.1159/000487091 a refinement to guidance for public health decision making is required if cystatin-C is to be considered a tool to "rule out" CKD as is currently suggested. Targeted cystatin-C measurement may be warranted in those with creatinine based EPI CKD stage 3A-a1 without pre-existing diabetes mellitus or hypertension.
Overall, our study suggests that in an unselected primary care CKD cohort, conversion from MDRD eGFR to CKD-EPI eGFR will increase overall population CKD prevalence bringing more individuals into the earliest stage of CKD. Whether this will practically alter care or lead to improvements or changes in outcomes for such patients remains unclear. However, this will lead to substantial initial costs of cystatin-C testing for healthcare services, estimated at approximately €67.5 (£57.2) million in the United Kingdom with further ongoing annual costs of €2.7 (£2.3) million. Therefore, further refinement of eGFR formulae, CKD definitions and eligibility for cystatin-C at an unselected population based level is required.
